Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback